Product ID: SQSG35I2029
Report ID:
SQSG35I2029 |
Region:
Global |
Published Date: February, 2024
Pages:
257
|
Tables:
95 |
Figures:
70
Myocardial Infarction (MI) Therapeutics Market was valued to be US$ 1.91 billion in 2019, and it is expected to reach US$ 2.65 billion by 2031 at a CAGR of 4.82% over the forecast period 2022 - 2028.
The main cause of myocardial infarction, often known as a heart attack, is coronary artery disease, which results in a decreased blood flow to the heart muscles. Myocardial infarction happens when an area of the heart loses oxygen because one of the coronary arteries is blocked. Typically, blockages form as a result of atherosclerotic plaque accumulation on artery walls. The septal, anterior, posterior, lateral, or inferior walls of the left ventricle of the heart are where myocardial infarctions are most often found. Thus, insufficient oxygen results in the death of cardiac tissue and a recognisable chest discomfort in humans, which causes myocardial infarction. Around 17.3 million people worldwide pass away from heart disease each year, with myocardial infarction being the main cause of death, according to the American Heart Association (AHA). This increases the requirement of treatments for myocardial infarction which leads to the growth of the myocardial infarction (MI) therapeutics market.
The growth of the market for myocardial infarction treatment is also due to the rising prevalence of cardiovascular disorders and the growing senior population. The increased frequency of obesity and chronic disorders like diabetes, hypertension, and chronic kidney disease are further reasons driving this market's expansion. Additionally, unhealthy lifestyle habits, excessive alcohol consumption, and drug use—including amphetamine and cocaine use—among the populace are significant risk factors for myocardial infarction. As a result, the market for myocardial infarction treatment and management products is expected to grow in the coming years. According to estimates, the global market for myocardial infarction treatments has the potential to be lucrative and to grow due to the rising popularity of efficient and secure treatment protocols. The market for myocardial infarction treatments may develop as a result of anticipated technology advancements that will create a plethora of chances for detecting specific blockages, monitoring cellular response, and determining hereditary predisposition.
US Myocardial Infarction (MI) Therapeutics Market is poised to grow at a sustainable CAGR for the next forecast year.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONMyocardial Infarction (MI) Therapeutics Market was valued to be US$ 1.91 billion in 2019, and it is expected to reach US$ 2.65 billion by 2031 at a CAGR of 4.82% over the forecast period 2022 - 2028.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQSG35I2029